Genomics Collaborative Inc. looks like two distinct businesses: a functional genomics company in Cambridge, MA and a clinical research organization in Blue Bell, PA. But they are really two halves of a single drug discovery company, says Michael Pellini, MD, CEO, one that possesses the analytical tools for genetic association studies and biological analysis and the patient biological samples to back them up.
Several years ago, the founders of GCI realized that the rate-limiting resource in genomics drug discovery was not technology but...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?